$41.5 Million Settlement – Zetia and Vytorin Lawsuit

Seeger Weiss Founding Partner, Christopher A. Seeger, Served as Chief Negotiator in the Nationwide Settlement Seeger Weiss LLP announced today a $41.5 million settlement with Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE: PGH) resolving nationwide fraud claims arising out of the sale and marketing of the companies’ co-ventured prescription drugs Zetia and […]

August 5, 2009

Zetia and Vytorin Lawsuit Settlement

Seeger Weiss Founding Partner, Christopher A. Seeger, Served as Chief Negotiator in the Nationwide Settlement

Seeger Weiss LLP announced today a $41.5 million settlement with Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE: PGH) resolving nationwide fraud claims arising out of the sale and marketing of the companies’ co-ventured prescription drugs Zetia and Vytorin. The claims, which sought cost reimbursements and other fraud-based damages, were brought by consumers and unions, employers and other thirdparty payers in federal proceedings in Newark, New Jersey before the Honorable Dennis M. Cavanaugh of the United States District Court in New Jersey.

The settlement, if approved by Judge Cavanaugh, will conclude over 140 actions coordinated for pretrial purposes under the caption, In Re Vytorin/Zetia Marketing, Sales Practices and Products Liability Litigation, in which Seeger Weiss founding partners, Christopher A. Seeger and Stephen A. Weiss, serve as Co-Liaison Counsel for the Plaintiffs’ Executive Committee, along with James E. Cecchi of Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein.

Under the agreement, in which Merck and Schering-Plough did not admit to liability, the companies will provide partial reimbursement to consumers and nongovernmental purchasers, including union health and welfare plans, self-insured employers, and insurers, who from November 1, 2002 through the date of the court’s settlement approval purchased Zetia and Vytorin prescriptions.

The lawsuits, which allege violations of the federal racketeering laws, accused Merck and Schering-Plough of engaging in a scheme to suppress 2006 results of clinical studies in order to prolong billions of dollars in annual sales expected to be lost with the expiration of Merck’s patent for the blockbuster cholesterol drug, Zocor, a statin. The scheme was also designed to enhance the sales of Zetia, a highly popular non-statin cholesterol drug patented by Schering-Plough, but marketed and sold jointly with Merck.

Plaintiffs contend that Merck conspired with Schering-Plough in 2003 to combine Zetia with Zocor under the Vytorin label. In so doing, the two companies began marketing Vytorin as more effective in reducing cholesterol than Zetia and Zocor alone, as well as being effective in blocking arterial plaque that can cause heart attack and stroke.

The lawsuits also allege that the companies have known since 2006 that Vytorin was no more effective than the generic version of Zocor in blocking plaque, despite being effective in lowering LDL, or “bad” cholesterol. In failing to disclose these facts, Merck and Schering-Plough were allegedly able to cause consumers and third-party purchasers to pay significantly higher prices than the cost of equally effective alternatives available on the market.

As Chris Seeger, who was the principal negotiator for the Plaintiffs’ Executive Committee, observed: “As individuals, businesses and other organizations struggle to pay for rising costs of healthcare, this settlement will help ease their burden. It will also put pharmaceutical companies on notice that they must play by the rules and fully disclose all material facts that are known to them so individuals can make informed choices on how they spend their health care dollars.”

Messrs. Seeger and Weiss were joined in the actions by Seeger Weiss partners Diogenes P. Kekatos and Jeffrey S. Grand.

About Seeger Weiss LLP

For the past decade, Seeger Weiss has served on the forefront of pharmaceutical, medical device and other mass-tort litigation. In addition to the Vytorin/Zetia actions, the firm has played leading roles in national pharmaceutical proceedings, including those involving Vioxx®, Zyprexa, Rezulin, Bextra, Dexatrim, Propulsid, to name a few. Currently, the firm maintains leadership positions in litigation involving Fosamax, Gadolinium, Accutane, Fleet Phospho-Soda , among others. With a team that includes former federal and state prosecutors, as well as trial attorneys from several of the nation’s largest and most highly respected defense firms, Seeger Weiss attorneys have earned reputations in the areas of drug and toxic injury; personal injury; class actions; securities litigation; environmental litigation; employment law; antitrust litigation; and commercial disputes. Seeger Weiss attorneys, along with co-counsel, have recovered more than $7 billion on behalf of firm clients and class members. With more than 30 attorneys, Seeger Weiss has offices in New York’s Financial District, Newark, NJ and Philadelphia, PA.

Related News

May 24, 2024
Lawdragon Names Nine Seeger Weiss Partners to 500 Plaintiff Financial Lawyers List

Seeger Weiss is proud to announce that Lawdragon recognized nine partners — Chris Seeger, Stephen Weiss, David Buchanan, Shauna Itri, Jennifer Scullion, Chris Ayers, Ben Barnett, Parvin Aminolroaya, and Steve Daroci — on the 2024 500 Leading Plaintiff Financial Lawyers list. This guide, first published in 2007 by Lawdragon Inc., presents Lawdragon’s opinion of “the […]

Read More
May 13, 2024
Seeger Weiss, Chris Seeger Named Elite Trial Lawyers Plaintiff Firm of the Year and Plaintiff Attorney of the Year Finalists; Parvin Aminolroaya Wins Elite Women of the Plaintiffs Bar Award

Seeger Weiss is pleased to announce that the firm and several of its partners have won or are finalists for multiple 2024 National Law Journal Elite Trial Lawyers Awards. Seeger Weiss was named a finalist for: Plaintiffs Firm of the Year Environmental Protection Practice Group of the Year Government Representation Practice Group of the Year […]

Read More
May 9, 2024
Seeger Weiss Reaches $1.1 Billion Personal Injury and Medical Monitoring Settlement in Philips CPAPs, Bi-PAPs, and Ventilators Litigation

Seeger Weiss founder and court-appointed co-lead counsel Chris Seeger secured a nearly $1.1 billion settlement in the Philips Recalled CPAP, Bi-Level Pap, and Mechanical Ventilator Products Litigation. The agreement provides $1.075 billion to compensate patients who suffered injuries while using recalled Philips devices and also includes $25 million to cover the cost of medical monitoring […]

Read More